1048041-45-7

Basic information

• Product Name: C₄₀H₅₁ClN₂O₇SSi
• Synonyms: C₄₀H₅₁ClN₂O₇SSi
• CAS NO: 1048041-45-7
• Molecular Weight: 767.459
• Mol File: 1048041-45-7.mol

Chemical Properties

• CAS DataBase Reference: C₄₀H₅₁ClN₂O₇SSi(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₀H₅₁ClN₂O₇SSi(1048041-45-7)
• EPA Substance Registry System: C₄₀H₅₁ClN₂O₇SSi(1048041-45-7)

Safety Data

• Hazardous Substances Data: 1048041-45-7(Hazardous Substances Data)

Upstream product

• 56146-83-9 chlorosulfonyl-acetic acid methyl ester 
• 1048041-44-6 C₃₇H₄₇ClN₂O₃Si 
• 59649-56-8 2,3-diaminophenol 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 13154-24-0 triisopropylsilyl chloride 
• 1048041-43-5 11-(4-benzyloxy-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-dibenzo[b,e][1,4]diazepin-1-one 
• 1048041-42-4 C₁₄H₁₈N₂O₂ 
• 603-85-0 2-Amino-3-nitrophenol 
• 117490-57-0 4-(benzyloxy)-2-chlorobenzaldehyde 
• 100-39-0 benzyl bromide 
• 853953-30-7 2-chloro-4-benzyloxybenzonitrile 

Downstream Products

• 1048041-23-1 C₃₁H₃₁ClN₂O₇S 
• 1048041-25-3 [11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetic acid 
• 1048041-26-4 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetamide 
• 1048041-29-7 11-(4-benzyloxy-2-chlorophenyl)-6-hydroxy-10-methanesulfonyl-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one 
• 1048041-27-5 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]-N-(1H-tetrazol-5-yl)acetamide 

Relevant articles and documents

10-SULFONYL-DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS

Inhibitors of HCV replication of formula (I) and the stereoisomers, prodrugs, tautomers, racemics, salts, hydrates or solvates thereof, wherein X, Y, R1; R2; R3; R4a and R4b have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.